FY25 consensus $6.51. Raises FY25 revenue view to $818M-$843M from $768M-$793M, consensus $791.48M. Raises FY25 adjusted EBITDA view to $213M-$223M from $195M-$205M.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- Is ANIP a Buy, Before Earnings?
- Positive Outlook on ANI Pharmaceuticals Despite Legal Setback: Buy Rating Reaffirmed
- ANI Pharmaceuticals to Challenge Court Verdict
- CG Oncology announces Delaware Superior Court ruling in its favor
- Optimistic Growth Potential for ANI Pharmaceuticals Despite Challenges in DME Treatment